Stifel Nicolaus Reiterates “Buy” Rating for Masimo (NASDAQ:MASI)

Stifel Nicolaus reaffirmed their buy rating on shares of Masimo (NASDAQ:MASI) in a research note issued to investors on Friday morning,Benzinga reports. Stifel Nicolaus currently has a $190.00 target price on the medical equipment provider’s stock, up from their previous target price of $170.00.

A number of other research analysts have also commented on the stock. Raymond James upgraded shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target for the company in a research report on Wednesday, November 6th. Piper Sandler boosted their price objective on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Wells Fargo & Company boosted their price target on shares of Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Finally, BTIG Research raised their price objective on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $167.00.

Masimo Stock Up 2.7 %

MASI opened at $177.70 on Friday. Masimo has a 12 month low of $91.60 and a 12 month high of $178.11. The company has a market cap of $9.51 billion, a PE ratio of 121.62 and a beta of 0.97. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average of $143.48 and a 200 day moving average of $128.00.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. During the same period in the previous year, the business earned $0.63 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. On average, sell-side analysts expect that Masimo will post 4.04 EPS for the current year.

Institutional Trading of Masimo

Several hedge funds and other institutional investors have recently bought and sold shares of MASI. NBC Securities Inc. grew its holdings in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares during the last quarter. GAMMA Investing LLC grew its holdings in Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 200 shares during the period. HHM Wealth Advisors LLC raised its stake in shares of Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the last quarter. Finally, Lazard Asset Management LLC raised its stake in shares of Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 573 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.